Article content
ZURICH International drug regulators have said the benefits of using COVID-19 vaccines developed by Johnson & Johnson and AstraZeneca outweigh risks as they investigate reports of extremely rare, but potentially fatal blood clots.
Several EU countries have restricted their use.
We apologize, but this video has failed to load.
Try refreshing your browser, or How worried should we be about blood clots linked to AstraZeneca, J&J vaccines? Back to video
Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasized that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-19 deaths and severe disease.
EU drug regulator reviewing woman s death in Belgium after getting J&J shot
whbl.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from whbl.com Daily Mail and Mail on Sunday newspapers.
EU persuades U S to ease COVID export restrictions for CureVac -sources
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
INSIGHT-Big promises, few doses: why Russia s struggling to make Sputnik V doses Reuters 3 hrs ago Russia has touted Sputnik V vaccine around world Vaccine production and exports lower than expected Manufacturers face a series of big challenges Hurdles serve as a warning to foreign partners (Updates to add comment from Russia s industry ministry)
By Polina Nikolskaya and Polina Ivanova
MOSCOW, May 14 (Reuters) - Transforming the site of what once was a Soviet-era car factory into a state-of-the-art facility churning out Russia s COVID-19 vaccine Sputnik V was the easy bit.
Making doses in bulk, finding qualified staff and getting equipment have been much bigger headaches for Moscow-based biotech firm R-Pharm and other private Russian companies picked to make the country s flagship shot to fight the pandemic.